home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Preserving Fertility during Cancer Treatment

  October, 1 2009 17:31
your information resource in human molecular genetics

A mechanism that accounts for the negative effects of chemotherapy on female fertility, and a potential way to prevent it with a well known drug, is reported online this week in Nature Medicine.

Infertility is a major side effect in young patients undergoing cancer treatment, owing to the sensitivity of germ cells to chemotherapy. Stefania Gonfloni and her colleagues report that cisplatin, a commonly used chemotherapeutic drug, activates a pro-cell death signaling pathway in female mouse germ cells. Cisplatin treatment ultimately induces germ-cell death by activating an enzyme known as c-Abl. When c-Abl is mutated, it causes chronic myeloid leukemia, which can be therapeutically targeted with imatinib, better known as Gleevec.

Crucially, the scientists also show that treatment with imatinib counteracts the cisplatin-induced cell death of the female germ cells. This raises the possibility of using imatinib to preserve germ cells and thus fertility during chemotherapy.

Author contact:

Stefania Gonfloni (University of Rome, Italy)
E-mail: stefania.gonfloni@uniroma2.it

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.